BOSTON--(BUSINESS WIRE)--PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Alberto Grignolo, Ph.D., Corporate Vice President, PAREXEL Consulting, has been named a Fellow by the Drug Information Association (DIA). Dr. Grignolo received the organization’s highest distinction during the 53rd DIA Annual Meeting in Chicago. The honorary designation recognizes Dr. Grignolo’s contributions to the advancement of health care and his leadership within DIA.
Dr. Grignolo, a 25-year veteran of PAREXEL, is a global expert on and a frequent contributor to various regulatory, drug development and management topics. At PAREXEL, he developed the Company’s Worldwide Regulatory Affairs and Drug Development Consulting Practices. He also established PAREXEL’s Consulting Services in Japan during an extended assignment there. Dr. Grignolo is executive sponsor of a number of global development programs and advises clients in the areas of drug development strategy, regulatory negotiation, and best regulatory and clinical practices.
Additionally, Dr. Grignolo served on the DIA Board of Directors, has been on the faculty of DIA’s Regulatory Affairs training courses for more than a decade, and is the Editor of DIA’s member magazine, Global Forum. In 2015, Dr. Grignolo was awarded the DIA Inspire Award (Global Connector) for his meritorious service through leadership roles that have advanced DIA’s mission to foster innovation and to improve health and well-being worldwide.
“Alberto’s quarter century of leadership at PAREXEL has furthered our mission of helping clients deliver new therapies to patients sooner,” said Josef von Rickenbach, Chairman and CEO, PAREXEL. “This recognition as a DIA Fellow also showcases his dedication to the advancement of health care. We are proud of his continued service and commitment to our Company and the many clients he serves.”
“Alberto personifies DIA. His commitment and passion for health care product innovation, along with his willingness to share candid insights from his treasure trove of knowledge, characterize his many contributions to DIA over the decades. We are thrilled to count Alberto amongst our leaders and volunteers, and honored to bestow upon him this well-deserved recognition of Fellow of DIA,” said Barbara Lopez Kunz, Global Chief Executive, DIA.
About Fellow of DIA Program
Membership into the Fellows of DIA Program is a unique distinction awarded to long-term, highly engaged members who continue to contribute to DIA in exemplary ways. This is an honorary recognition bestowed on less than 1 percent of DIA’s membership.
Fellows of DIA have demonstrated active support of the advancement of health care and the health care products arena through leadership roles for a minimum of 15 years and have proven engagement in DIA through key volunteer roles in support of major DIA projects or initiatives.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the integrated clinical development and regulatory information management process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 86 locations in 51 countries around the world, and had approximately 19,370 employees in the third quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.